A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...